Do analysts recommend ATHE or CRDL?

Cardiol Therapeutics has a consensus price target of $8.50, indicating a potential upside of 687.04%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cardiol Therapeutics is more favorable than Alterity Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alterity Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cardiol Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has better earnings & valuation, ATHE or CRDL?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alterity Therapeutics N/A N/A -$7.87M N/A N/A Cardiol Therapeutics N/A N/A -$24.20M -$0.28 N/A

Is ATHE or CRDL more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Alterity Therapeutics N/A N/A N/A Cardiol Therapeutics N/A -229.43% -165.60%

Do analysts prefer ATHE or SPRB?

Spruce Biosciences has a consensus target price of $176.60, suggesting a potential upside of 258.07%. Given Spruce Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Spruce Biosciences is more favorable than Alterity Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alterity Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Spruce Biosciences 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has higher valuation & earnings, ATHE or SPRB?

Alterity Therapeutics has higher earnings, but lower revenue than Spruce Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alterity Therapeutics N/A N/A -$7.87M N/A N/A Spruce Biosciences $4.91M 27.62 -$38.97M -$36.60 N/A

Is ATHE or SPRB more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Spruce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Alterity Therapeutics N/A N/A N/A Spruce Biosciences N/A -155.40% -101.67%

Do analysts rate ACOG or ATHE?

Alpha Cognition presently has a consensus target price of $14.67, indicating a potential upside of 143.63%. Given Alpha Cognition's stronger consensus rating and higher probable upside, analysts clearly believe Alpha Cognition is more favorable than Alterity Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alpha Cognition 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Alterity Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation and earnings, ACOG or ATHE?

Alterity Therapeutics has lower revenue, but higher earnings than Alpha Cognition. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alpha Cognition $10.83M 12.11 -$20.67M -$1.35 N/A Alterity Therapeutics N/A N/A -$7.87M N/A N/A

Do analysts recommend VTVT or ATHE?

vTv Therapeutics currently has a consensus price target of $53.00, indicating a potential upside of 65.32%. Given vTv Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe vTv Therapeutics is more favorable than Alterity Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score vTv Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86 Alterity Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings and valuation, VTVT or ATHE?

Alterity Therapeutics has lower revenue, but higher earnings than vTv Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio vTv Therapeutics $1.02M 123.84 -$26.97M -$0.93 N/A Alterity Therapeutics N/A N/A -$7.87M N/A N/A

Is VTVT or ATHE more profitable?

vTv Therapeutics' return on equity of 3.96% beat Alterity Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets vTv Therapeutics N/A 3.96% 2.86% Alterity Therapeutics N/A N/A N/A

Do analysts rate GNLX or ATHE?

Genelux currently has a consensus price target of $18.00, suggesting a potential upside of 514.33%. Given Genelux's stronger consensus rating and higher possible upside, research analysts clearly believe Genelux is more favorable than Alterity Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genelux 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Alterity Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation and earnings, GNLX or ATHE?

Alterity Therapeutics has lower revenue, but higher earnings than Genelux. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genelux $10K 13,138.12 -$32.15M -$0.85 N/A Alterity Therapeutics N/A N/A -$7.87M N/A N/A

Is GNLX or ATHE more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Genelux N/A -174.55% -123.65% Alterity Therapeutics N/A N/A N/A

Alterity Therapeutics (ATHE) Competitors

$3.92 +0.02 (+0.51%)

Closing price 06/8/2026 02:53 PM Eastern

Extended Trading

$4.43 +0.52 (+13.14%)

As of 05:27 AM Eastern

Compare

ATHE vs. CRDL, SPRB, ACOG, VTVT, and GNLX

Should you buy Alterity Therapeutics stock or one of its competitors? MarketBeat compares Alterity Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alterity Therapeutics include Cardiol Therapeutics (CRDL), Spruce Biosciences (SPRB), Alpha Cognition (ACOG), vTv Therapeutics (VTVT), and Genelux (GNLX). These companies are all part of the "pharmaceutical products" industry.

How does Alterity Therapeutics compare to Cardiol Therapeutics?

Alterity Therapeutics (NASDAQ:ATHE) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A

2.1% of Alterity Therapeutics shares are owned by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are owned by institutional investors. 38.8% of Alterity Therapeutics shares are owned by company insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Alterity Therapeutics' average media sentiment score of 0.00 equaled Cardiol Therapeutics'average media sentiment score.

Company	Overall Sentiment
Alterity Therapeutics	Neutral
Cardiol Therapeutics	Neutral

Cardiol Therapeutics has a consensus price target of $8.50, indicating a potential upside of 687.04%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cardiol Therapeutics is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Alterity Therapeutics has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market.

Alterity Therapeutics' return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alterity Therapeutics	N/A	N/A	N/A
Cardiol Therapeutics	N/A	-229.43%	-165.60%

Summary

Cardiol Therapeutics beats Alterity Therapeutics on 5 of the 9 factors compared between the two stocks.

How does Alterity Therapeutics compare to Spruce Biosciences?

Alterity Therapeutics (NASDAQ:ATHE) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

Alterity Therapeutics has higher earnings, but lower revenue than Spruce Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A
Spruce Biosciences	$4.91M	27.62	-$38.97M	-$36.60	N/A

In the previous week, Spruce Biosciences had 10 more articles in the media than Alterity Therapeutics. MarketBeat recorded 10 mentions for Spruce Biosciences and 0 mentions for Alterity Therapeutics. Spruce Biosciences' average media sentiment score of 0.87 beat Alterity Therapeutics' score of 0.00 indicating that Spruce Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Alterity Therapeutics	Neutral
Spruce Biosciences	Positive

Alterity Therapeutics' return on equity of 0.00% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alterity Therapeutics	N/A	N/A	N/A
Spruce Biosciences	N/A	-155.40%	-101.67%

2.1% of Alterity Therapeutics shares are owned by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are owned by institutional investors. 38.8% of Alterity Therapeutics shares are owned by insiders. Comparatively, 4.3% of Spruce Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Alterity Therapeutics has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market. Comparatively, Spruce Biosciences has a beta of 3.12, suggesting that its stock price is 212% more volatile than the broader market.

Spruce Biosciences has a consensus target price of $176.60, suggesting a potential upside of 258.07%. Given Spruce Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Spruce Biosciences is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Spruce Biosciences beats Alterity Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Alterity Therapeutics compare to Alpha Cognition?

Alpha Cognition (NASDAQ:ACOG) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Alterity Therapeutics has a net margin of 0.00% compared to Alpha Cognition's net margin of -232.23%. Alterity Therapeutics' return on equity of 0.00% beat Alpha Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	-232.23%	-58.35%	-45.99%
Alterity Therapeutics	N/A	N/A	N/A

Alterity Therapeutics has lower revenue, but higher earnings than Alpha Cognition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Cognition	$10.83M	12.11	-$20.67M	-$1.35	N/A
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A

Alpha Cognition has a beta of 2.36, indicating that its stock price is 136% more volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market.

Alpha Cognition presently has a consensus target price of $14.67, indicating a potential upside of 143.63%. Given Alpha Cognition's stronger consensus rating and higher probable upside, analysts clearly believe Alpha Cognition is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Alpha Cognition's average media sentiment score of 0.00 equaled Alterity Therapeutics'average media sentiment score.

Company	Overall Sentiment
Alpha Cognition	Neutral
Alterity Therapeutics	Neutral

2.1% of Alterity Therapeutics shares are owned by institutional investors. 14.0% of Alpha Cognition shares are owned by insiders. Comparatively, 38.8% of Alterity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Alterity Therapeutics beats Alpha Cognition on 6 of the 11 factors compared between the two stocks.

How does Alterity Therapeutics compare to vTv Therapeutics?

vTv Therapeutics (NASDAQ:VTVT) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

vTv Therapeutics has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

In the previous week, vTv Therapeutics had 2 more articles in the media than Alterity Therapeutics. MarketBeat recorded 2 mentions for vTv Therapeutics and 0 mentions for Alterity Therapeutics. vTv Therapeutics' average media sentiment score of 0.00 equaled Alterity Therapeutics'average media sentiment score.

Company	Overall Sentiment
vTv Therapeutics	Neutral
Alterity Therapeutics	Neutral

17.5% of vTv Therapeutics shares are owned by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are owned by institutional investors. 6.0% of vTv Therapeutics shares are owned by insiders. Comparatively, 38.8% of Alterity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

vTv Therapeutics' return on equity of 3.96% beat Alterity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
vTv Therapeutics	N/A	3.96%	2.86%
Alterity Therapeutics	N/A	N/A	N/A

vTv Therapeutics currently has a consensus price target of $53.00, indicating a potential upside of 65.32%. Given vTv Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe vTv Therapeutics is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
vTv Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Alterity Therapeutics has lower revenue, but higher earnings than vTv Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
vTv Therapeutics	$1.02M	123.84	-$26.97M	-$0.93	N/A
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A

Summary

vTv Therapeutics beats Alterity Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Alterity Therapeutics compare to Genelux?

Genelux (NASDAQ:GNLX) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.

37.3% of Genelux shares are held by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are held by institutional investors. 7.5% of Genelux shares are held by company insiders. Comparatively, 38.8% of Alterity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Alterity Therapeutics' return on equity of 0.00% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-174.55%	-123.65%
Alterity Therapeutics	N/A	N/A	N/A

Alterity Therapeutics has lower revenue, but higher earnings than Genelux.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$10K	13,138.12	-$32.15M	-$0.85	N/A
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A

Genelux has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market.

Genelux currently has a consensus price target of $18.00, suggesting a potential upside of 514.33%. Given Genelux's stronger consensus rating and higher possible upside, research analysts clearly believe Genelux is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Genelux had 3 more articles in the media than Alterity Therapeutics. MarketBeat recorded 3 mentions for Genelux and 0 mentions for Alterity Therapeutics. Alterity Therapeutics' average media sentiment score of 0.00 beat Genelux's score of -0.05 indicating that Alterity Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Genelux	Neutral
Alterity Therapeutics	Neutral

Summary

Genelux beats Alterity Therapeutics on 7 of the 12 factors compared between the two stocks.

Get Alterity Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATHE vs. The Competition

Export

Metric	Alterity Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$34.58M	$3.34B	$6.48B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.58%
P/E Ratio	N/A	18.61	23.69	23.74
Price / Sales	N/A	296.61	513.81	108.85
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	1.26	8.04	10.41	6.78
Net Income	-$7.87M	$23.89M	$3.57B	$337.51M
7 Day Performance	-2.34%	-3.28%	0.28%	-2.34%
1 Month Performance	-15.88%	2.78%	3.27%	1.88%
1 Year Performance	-19.01%	36.03%	22.25%	25.55%

Alterity Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATHE Alterity Therapeutics	0.8583 of 5 stars	$3.92 +0.5%	N/A	-17.1%	$34.58M	N/A	N/A	10	Positive News
CRDL Cardiol Therapeutics	1.7786 of 5 stars	$1.15 -5.7%	$8.50 +639.1%	-23.4%	$140.60M	N/A	N/A	20
SPRB Spruce Biosciences	2.753 of 5 stars	$49.30 -2.8%	$176.60 +258.2%	+929.1%	$139.54M	$4.91M	N/A	20	News Coverage
ACOG Alpha Cognition	3.1344 of 5 stars	$6.18 -2.5%	$14.67 +137.3%	-35.8%	$138.05M	$10.22M	N/A	N/A
VTVT vTv Therapeutics	2.2914 of 5 stars	$33.00 -3.8%	$53.00 +60.6%	+92.3%	$135.10M	$1.02M	N/A	9	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATHE) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alterity Therapeutics (ATHE) Competitors

ATHE vs. CRDL, SPRB, ACOG, VTVT, and GNLX

How does Alterity Therapeutics compare to Cardiol Therapeutics?

Summary

How does Alterity Therapeutics compare to Spruce Biosciences?

Summary

How does Alterity Therapeutics compare to Alpha Cognition?

Summary

How does Alterity Therapeutics compare to vTv Therapeutics?

Summary

How does Alterity Therapeutics compare to Genelux?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATHE vs. The Competition

Alterity Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alterity Therapeutics (ATHE) Competitors

ATHE vs. CRDL, SPRB, ACOG, VTVT, and GNLX

How does Alterity Therapeutics compare to Cardiol Therapeutics?

Which has better earnings & valuation, ATHE or CRDL?

Do insiders & institutionals believe in ATHE or CRDL?

Does the media refer more to ATHE or CRDL?

Do analysts recommend ATHE or CRDL?

Which has more risk & volatility, ATHE or CRDL?

Is ATHE or CRDL more profitable?

Summary

How does Alterity Therapeutics compare to Spruce Biosciences?

Which has higher valuation & earnings, ATHE or SPRB?

Does the media favor ATHE or SPRB?

Is ATHE or SPRB more profitable?

Do institutionals and insiders have more ownership in ATHE or SPRB?

Which has more risk & volatility, ATHE or SPRB?

Do analysts prefer ATHE or SPRB?

Summary

How does Alterity Therapeutics compare to Alpha Cognition?

Is ACOG or ATHE more profitable?

Which has stronger valuation and earnings, ACOG or ATHE?

Which has more risk & volatility, ACOG or ATHE?

Do analysts rate ACOG or ATHE?

Does the media refer more to ACOG or ATHE?

Do institutionals & insiders believe in ACOG or ATHE?

Summary

How does Alterity Therapeutics compare to vTv Therapeutics?

Which has more risk & volatility, VTVT or ATHE?

Does the media prefer VTVT or ATHE?

Do institutionals & insiders believe in VTVT or ATHE?

Is VTVT or ATHE more profitable?

Do analysts recommend VTVT or ATHE?

Which has stronger earnings and valuation, VTVT or ATHE?

Summary

How does Alterity Therapeutics compare to Genelux?

Do insiders and institutionals have more ownership in GNLX or ATHE?

Is GNLX or ATHE more profitable?

Which has stronger valuation and earnings, GNLX or ATHE?

Which has more risk & volatility, GNLX or ATHE?

Do analysts rate GNLX or ATHE?

Does the media prefer GNLX or ATHE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATHE vs. The Competition

Alterity Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools